Get the Stockscreener App
1.88
0.00%
0.00
After Hours:
1.96
0.08
+4.26%
Humacyte Inc stock is traded at $1.88, with a volume of 5.64M.
It is up +0.00% in the last 24 hours and down -17.54% over the past month.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
See More
Previous Close:
$1.88
Open:
$1.9
24h Volume:
5.64M
Relative Volume:
1.19
Market Cap:
$291.62M
Revenue:
-
Net Income/Loss:
$-110.78M
P/E Ratio:
-1.757
EPS:
-1.07
Net Cash Flow:
$-75.59M
1W Performance:
-24.19%
1M Performance:
-17.54%
6M Performance:
-51.92%
1Y Performance:
-69.38%
1-Day Range:
$1.87
$2.02
1-Week Range:
$1.6012
$2.05
52-Week Range:
$1.15
$7.48
Humacyte Inc Stock (HUMA) Company Profile
Name
Humacyte Inc
Sector
Industry
Phone
919-313-9633
Address
2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
Compare HUMA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HUMA
Humacyte Inc
|
1.88 | 297.74M | 0 | -110.78M | -75.59M | -1.07 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Humacyte Inc Stock (HUMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-14-25 | Resumed | H.C. Wainwright | Buy |
| Dec-20-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-11-23 | Initiated | H.C. Wainwright | Buy |
| Aug-14-23 | Upgrade | Piper Sandler | Underweight → Neutral |
| Jun-22-23 | Initiated | Cantor Fitzgerald | Overweight |
| May-16-22 | Downgrade | Piper Sandler | Overweight → Underweight |
| Oct-29-21 | Initiated | Cowen | Outperform |
| Sep-24-21 | Initiated | Oppenheimer | Outperform |
| Sep-22-21 | Initiated | BTIG Research | Buy |
| Sep-16-21 | Initiated | Piper Sandler | Overweight |
View All
Humacyte Inc Stock (HUMA) Latest News
Humacyte Reports Q2 2025 Earnings and Market Expansion - TipRanks
Will Humacyte Inc. outperform during market ralliesQuarterly Portfolio Summary & Fast Gaining Stock Reports - newsyoung.net
Humacyte, Inc. (HUMA) Stock Declines While Market Improves: Some Information for Investors - MSN
Earnings call transcript: Humacyte Q2 2025 misses EPS and revenue targets - Investing.com Australia
MACD Cross Could Confirm Trend in Humacyte Inc.2025 Technical Patterns & Verified Short-Term Trading Plans - thegnnews.com
Trading Bots Trigger Alerts on Humacyte Inc. ActivityJuly 2025 Recap & Free High Return Stock Watch Alerts - metal.it
A Quick Look at Today's Ratings for Humacyte(HUMA.US), With a Forecast Between $3 to $14 - 富途牛牛
Humacyte: Cash Burn And A Glacial Launch Overshadow VAC Progress (NASDAQ:HUMA) - Seeking Alpha
Humacyte stock price target lowered to $3.50 at TD Cowen on mixed outlook - Investing.com Canada
Humacyte stock rating reiterated at Buy by Benchmark despite revenue miss - Investing.com Canada
Humacyte, Inc. (NASDAQ:HUMA) Q2 2025 Earnings Call Transcript - Insider Monkey
H.C. Wainwright lowers Humacyte stock price target to $3 on weak sales - Investing.com Canada
Analysts Expect Breakeven For Humacyte, Inc. (NASDAQ:HUMA) Before Long - simplywall.st
Humacyte targets over 200 hospital access points for Symvess as VAC approvals surge and cost cuts extend cash runway - MSN
Humacyte Inc (HUMA) Q2 2025 Earnings Call Highlights: Navigating Challenges and Celebrating ... By GuruFocus - Investing.com Canada
Humacyte Inc Navigates Challenges, Celebrates Milestones in Q2 2025 Earnings Call Highlights - AInvest
Humacyte Reports Q2 Revenue Miss, Symvess Shows Progress in Hospital Access and Sales - AInvest
Humacyte Missed Revenue Forecasts But Expanded Symvess Access - Finimize
Humacyte Posts Q2 Revenue Miss - AOL.com
Humacyte: D. Boral Capital Maintains Buy, PT Raised to $25 from $20. - AInvest
Humacyte, Inc. shares fall 31.49% intraday after reporting Q2 revenue of $301,000, far below analyst expectations of $1 million. - AInvest
Humacyte stock price target lowered to $7 at BTIG on mixed Q2 results - Investing.com Canada
Humacyte's 2025 Q2 Earnings Call: Unpacking Key Contradictions on Sales, CMS Impact, and FDA Interactions - AInvest
Sitryx gets back rights to drug from Lilly deal; Humacyte is cutting costs - Endpoints News
Humacyte Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Transcript : Humacyte, Inc., Q2 2025 Earnings Call, Aug 11, 2025 - MarketScreener
Humacyte, Inc. (HUMA) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Humacyte Plunges 10.08% on Disappointing Earnings - AInvest
Assessing Humacyte's Long-Term Viability: A Cautionary Tale of Recurring Losses and Revenue Shortfalls - AInvest
Humacyte earnings missed by $0.08, revenue fell short of estimates - Investing.com Canada
Humacyte Posts Q2 Revenue Miss - The Motley Fool
Humacyte misses Q2 revenue estimates, net loss narrows - MarketScreener
Humacyte Announces Second Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Humacyte Q2 Earnings: Military Hospitals Join 277-Strong Network as Product Sales Hit Record High - Stock Titan
Is Humacyte Inc. forming a double bottomBottom Formation Alert - mustnews.co.kr
Humacyte HUMA Q2 2025 Earnings Preview Upside Potential Driven by Product Innovations - AInvest
Humacyte to Present Second Quarter Financial Results and Provide Corporate Update on August 11, 2025 - The Manila Times
Humacyte Q2 FY23: Revenue $11.1mln, down 23% YoY. - AInvest
Humacyte Q2 Earnings: Bioengineered Tissue Pioneer Reveals Latest Financial Performance - Stock Titan
Humacyte, Inc. (HUMA) Stock Dips While Market Gains: Key Facts - Yahoo Finance
What are Humacyte Inc. Equity Warrant company’s key revenue driversMassive stock growth - Jammu Links News
How does Humacyte Inc. Equity Warrant compare to its industry peersSuperior profit margins - Jammu Links News
Why is Humacyte Inc. stock attracting strong analyst attentionExceptional gains - Jammu Links News
What are Humacyte Inc. company’s key revenue driversAccess powerful market insights for free - Jammu Links News
What makes Humacyte Inc. stock price move sharplyUnlock powerful market trend analysis - Jammu Links News
How does Humacyte Inc. compare to its industry peersUnlock powerful market insights for success - Jammu Links News
What institutional investors are buying Humacyte Inc. stockFree Daily Trading Room Entry - Jammu Links News
Why is Humacyte Inc. Equity Warrant stock attracting strong analyst attentionMaximize gains with timely market signals - Jammu Links News
Should I hold or sell Humacyte Inc. Equity Warrant stock in 2025High-velocity capital appreciation - Jammu Links News
Is Humacyte Inc. a growth stock or a value stockDiscover the next big stock winners - Jammu Links News
Is Humacyte Inc. stock overvalued or undervaluedCapitalize on emerging investment opportunities - Jammu Links News
Humacyte Inc Stock (HUMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.41%
0.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):